Učitavanje...
ASCO Provisional Clinical Opinion: KRAS, Cetuximab, and Panitumumab—Clinical Implications in Colorectal Cancer
ASCO's Provisional Clinical Opinion alerts oncologists to emerging information from recent clinical trials that can assist them in treatment selection. Evidence suggests that cetuximab and panitumumab are ineffective in patients with KRAS mutations at codon 12 or 13. Thus, patients with colorec...
Spremljeno u:
| Glavni autori: | , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
American Society of Clinical Oncology
2009
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2790641/ https://ncbi.nlm.nih.gov/pubmed/20856723 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JOP.0924603 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|